AUSINDUSTRY CONFIRMS CONTINUATION OF POOLED DEVELOPMENT FUND PROGRAM

Acrux (ASX: ACR) is pleased to announce that the Australian Government review of proposed changes to the venture capital tax concession programs has concluded and determined that the Pooled Development Fund program will continue to be delivered in its current form. This affirms Acrux' ongoing status as a Pooled Development Fund (PDF).

Shareholders of Acrux will therefore continue to be entitled to concessionary tax treatment of income and capital gains derived from their shareholding. Dividends received by Australian shareholders are exempt from income tax while dividends received by foreign shareholders are not subject to withholding tax. Capital gains made by Australian shareholders are exempt from Australian tax while capital losses are not deductable. Acrux's 2014 annual report contains further taxation information relevant to PDFs.

Mr Ross Dobinson, Executive Chairman, commented "We are pleased that the outcome of the review has been determined, and as anticipated, supports the continuation of this important program".

Contact

Ross Dobinson, Chairman: 03 9691 5920

About Acrux www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including AXIRON®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.